Replacing smear microscopy for the diagnosis of tuberculosis: What is the market potential?

European Respiratory Journal

Volumn 43, Issue 6, 2014, Pages 1793-1796

  Kik, Sandra V ^a,b   Denkinger, Claudia M ^a,b,c   Chedore, Pamela ^a,b   Pai, Madhukar ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG RESISTANCE; FINANCIAL MANAGEMENT; HEALTH CARE COST; HUMAN; LETTER; LUNG TUBERCULOSIS; MARKETING; MOLECULAR DIAGNOSIS; MOLECULAR DIAGNOSTICS; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SPUTUM CYTODIAGNOSIS; SPUTUM SMEAR; DIAGNOSTIC KIT; DNA SEQUENCE; HEALTH; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MICROSCOPY; MYCOBACTERIUM TUBERCULOSIS; PROCEDURES; SENSITIVITY AND SPECIFICITY; SPUTUM; TUBERCULOSIS, PULMONARY;

DIAGNOSTIC KIT;

BACTERIOLOGICAL TECHNIQUES; GLOBAL HEALTH; HUMANS; MICROSCOPY; MYCOBACTERIUM TUBERCULOSIS; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; SPUTUM; TUBERCULOSIS, PULMONARY;

EID: 84901827201     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00217313     Document Type: Letter

References (14)

1. Denkinger CM, Kik SV, Pai M. Robust, reliable and resilient: designing molecular tuberculosis tests for microscopy centers in developing countries. Expert Rev Mol Diagn 2013; 13: 763-776.
2. Pai NP, Vadnais C, Denkinger C, et al. Point-of-care testing for infectious diseases: diversity, complexity, andbarriers in low- and middle-income countries. PLoS Med 2012; 9: e1001306.
3. Lawn SD, Mwaba P, Bates M, et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and futureprospects for a point-of-care test. Lancet Infect Dis 2013; 13: 349-361.
4. Niemz A, Boyle DS. Nucleic acid testing for tuberculosis at the point-of-care in high-burden countries. Expert RevMol Diagn 2012; 12: 687-701.
5. UNITAID. Tuberculosis: Diagnostics Technology Landscape. Geneva, WHO, 2013.
6. Denkinger CM, Nicolau I, Ramsay A, et al. Are peripheral microscopy centres ready for next generation moleculartuberculosis diagnostics? Eur Respir J 2013; 42: 544-547.
7. Weyer K, Mirzayev F, Migliori GB, et al. Rapid molecular TB diagnosis: evidence, policy making and globalimplementation of Xpert MTB/RIF. Eur Respir J 2013; 42: 252-271.
8. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneousdetection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system for the diagnosis of pulmonary andextrapulmonary TB in adults and children. Policy Update. Geneva, WHO, 2013.
9. Pai M. Diagnostics for tuberculosis: what test developers want to know. Expert Rev Mol Diagn 2013; 13: 311-314.
10. World Health Organization/Special Programme for Research & Training in Tropical Diseases/Foundation forInnovative New Diagnostics. Diagnostics for tuberculosis. Global demand and market potential. Geneva, WHO,2006.
11. Lu C, Liu Q, Sarma A, et al. A systematic review of reported cost for smear and culture tests during multidrug-resistanttuberculosis treatment. PLoS One 2013; 8: e56074.
12. World Health Organization. Global Tuberculosis Report 2013. Geneva, WHO, 2013.
13. Wells WA, Ge CF, Patel N, et al. Size and usage patterns of private TB drug markets in the high burden countries.PLoS One 2011; 6: e18964.
14. Pantoja A, Fitzpatrick C, Vassall A, et al. Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistanttuberculosis: a cost and affordability analysis. Eur Respir J 2013; 42: 708-720.